Physician profile
Mary E Vajgrt
NPI 1396713509
$1,710.84
in general payments reported to CMS, 2019-2025
20 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.67 · 2023: $523 · 2024: $1,000 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $297.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $176.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.51 | 2023-2024 | Breztri, Farxiga, Flumist Quadrivalent |
| Abbott Laboratories | $153.89 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $127.09 | 2023-2024 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $116.89 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.95 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Amgen INC. | $107.88 | 2024-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $83.77 | 2023-2025 | Gardasil 9, Gardasil, Vaxelis |
| Astellas Pharma US INC | $75.95 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $71.56 | 2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $42.58 | 2023 | |
| Phadia US INC. | $31.38 | 2024-2025 | Immunocap |
| Mylan Specialty L.P. | $31.26 | 2024 | Yupelri |
| Alnylam Pharmaceuticals INC. | $27.81 | 2024 | Givlaari |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $19.98 | 2024 | Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2024 | Trintellix |
| Hologic Sales and Service, LLC | $17.69 | 2023 | Thinprep 2000 Processor, Aptima |
| Janssen Pharmaceuticals, INC | $17.40 | 2024 | Spravato |
| Sanofi Pasteur INC. | $15.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Vajgrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.